Liver Diseases  >>  grazoprevir (MK-5172)  >>  Phase 1
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
grazoprevir (MK-5172) / Merck (MSD)
NCT01547312: Evaluation of Hepatic Pharmacokinetics for Grazoprevir (MK-5172) in Participants With Chronic Hepatitis C (MK-5172-022)

Withdrawn
1
0
US
Peg-Interferon, PegIntron, Liver Samples from FNA, Liver Samples from CNB, Blood Samples, Ribavirin, Rebetol, 800 mg Grazoprevir, 100 mg Grazoprevir, Liver samples from CNB and FNA
Merck Sharp & Dohme LLC
Chronic Hepatitis C
11/12
11/12
NCT00998985: A Study of Grazoprevir (MK-5172) in Hepatitis C-Infected Male Participants (MK-5172-004)

Completed
1
91
NA
Grazoprevir, Placebo
Merck Sharp & Dohme LLC
Hepatitis C
11/12
11/12
NCT01537900: A Multiple Dose Study of Grazoprevir (MK-5172) in Hepatitis C-Infected Participants (MK-5172-010)

Completed
1
4
NA
Grazoprevir, MK-5172
Merck Sharp & Dohme LLC
Hepatitis C
07/14
07/14
NCT01390428: Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of Grazoprevir (MK-5172-013)

Completed
1
50
NA
Grazoprevir
Merck Sharp & Dohme LLC
Hepatitis C
09/14
09/14

Download Options